Frailty phenotype and the role of levodopa challenge test in geriatric inpatients with mild parkinsonian signs

• Published in: Biogerontology (Dordrecht) 2017-08, Vol.18 (4), p.641-650
• Main Authors: Seiffert, Piotr, Derejczyk, Jarosław, Kawa, Jacek, Marcisz, Czesław, Czernek, Małgorzata, Szymszal, Jan, Kapko, Wojciech, Bugdol, Monika, Torbus, Anna, Stępień-Wyrobiec, Olga
• Format: Article
• Language: English
• Subjects: Age Factors; Aged; Aged, 80 and over; Aging; Basal ganglia; Benserazide - administration & dosage; Biomedical and Life Sciences; Case-Control Studies; Cell Biology; Central nervous system diseases; Cross-Sectional Studies; Developmental Biology; Dopamine - metabolism; Dopamine Agents - administration & dosage; Dopamine receptors; Drug Combinations; Female; Frail Elderly; Frailty; Frailty - diagnosis; Frailty - epidemiology; Frailty - metabolism; Frailty - physiopathology; Geriatric Assessment - methods; Geriatrics; Geriatrics/Gerontology; Humans; Inpatients; Levodopa; Levodopa - administration & dosage; Life Sciences; Male; Movement disorders; Parkinson Disease - diagnosis; Parkinson Disease - epidemiology; Parkinson Disease - metabolism; Parkinson Disease - physiopathology; Phenotype; Poland - epidemiology; Predictive Value of Tests; Prevalence; Research Article; Severity of Illness Index
• ISSN: 1389-5729; 1573-6768
• DOI: 10.1007/s10522-017-9716-6

Deficiency in dopaminergic system function may be one of the hypothetical reasons of the frailty syndrome but its role still remains unclear. The aim of our study was to assess the frailty phenotype prevalence in geriatric inpatients with mild parkinsonian signs (MPS) and to investigate levodopa test in the frail patients with MPS. We examined 118 participants: 90 with MPS and 28 in control group (without MPS). The frailty syndrome presence was evaluated by the Fried criteria. Deficiency in dopaminergic system function was assessed by one of the modifications of an acute levodopa challenge test (LCT): in MPS group every patient was examined by performing Up and Go Test and also Step Test before and 3 h after taking 125 mg of Madopar (levodopa + benserazide). Sixty-nine study subjects (58%) met criteria for frailty. Fifty-five participants in MPS group (61.1% of MPS group) and fourteen (50%) in control group. All of the patients that scored positive in walk speed criterion of frailty were frail. When all MPS patients were considered, the number of components scored positive for frailty was directly related to the walk speed (r = −0.70, p